23 C
March 5, 2024
The Hona News

Triplet therapy including belamaf prolongs survival in multiple myeloma

For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to a study presented during the February 2024 session of the American Society for Clinical Oncology Plenary Series.

Source link

Related posts

CDC: Chronic fatigue syndrome prevalence 1.3 percent in 2021 to 2022


Wegovy: Why half of those taking it stop within a year, and what happens when they do


How can children, adolescents and adults who are overweight or obese be motivated to participate in health programs?


Leave a Comment